Filgotinib may be associated with a lower risk of herpes zoster compared with other Janus kinase inhibitors in rheumatoid arthritis.

IGNYTE showed that patients with confirmed progression on an anti-PD-1-based regimen who received RP1 plus nivolumab had a 34% response rate, with a median duration of 24.8 months, and 15% of them ...

Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from two Phase 3 trials evaluating the efficacy and safety of LITFULO once daily in patients with both active and stable nonsegmental ...

HSV-1 – WHO’s report breaks down herpes symptoms, prevention, treatment, and why stigma is the real problem. | Health ...

A webcast of the presentation will be available by selecting Events and Presentations in the Investors section of Candel’s website at www.candeltx.com. A replay of the webcast will be archived for up ...

India launches an AI and genomics-based precision oncology ecosystem to strengthen cancer diagnosis, early detection, and ...

AbbVie today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the ...

AbbVie today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with ...

Herpetic infection signals differ across targeted therapies for patients with AD, including for overall and type-specific herpetic infections.

ABL Diagnostics (Euronext Paris – Compartiment B – ISIN: FR001400AHX6), a company specialized in molecular diagnostic solutions for infectious diseases, announces the commercial availability of ...

Japan: In an exploratory randomized trial from Japan, patients with rheumatoid arthritis who started the JAK inhibitor ...